Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07019844 · ClinicalTrials.gov registry record
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
A clinical trial of Hepatocellular Carcinoma (HCC), sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- 90
- Enrollment target
- 1
- Study location
NCT07019844: Recruiting study of Hepatocellular Carcinoma (HCC), sponsored by VA Office of Research and Development.
NCT07019844 is a study of Hepatocellular Carcinoma (HCC) that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 90 participants, below the 345-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07019844, a study of Hepatocellular Carcinoma (HCC), is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.
Primary Outcome
1. Proportion of patients with LI-RADS 3/4 lesions whose diagnostic classification is revised (i.e., confirmed as HCC or benign) based on F18-Piflufolastat PET/CT findings, as compared to standard imaging alone. Final diagnosis will be based on histopathology (if available) or multidisciplinary tumor board consensus; 2. Number and percentage of treatment-naïve patients whose disease stage is upstaged or down-staged after PSMA PET/CT imaging, relative to standard imaging, according to modified BC
Conditions Studied
Study Locations (1)
Florida
- Miami VA Healthcare System, Miami, FL - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2028-09-30 |
What NCT07019844 shows while recruiting
NCT07019844 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 345-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Hepatocellular Carcinoma (HCC) appearing as the primary indexed condition, and to 0 interventions.
NCT07019844 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07019844 about?
NCT07019844 is a clinical study titled "PSMA PET for the Staging and Management of Hepatocellular Carcinoma". This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accu...
What is the current status of trial NCT07019844?
This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2024-09-19. Estimated completion is 2028-09-30.
What conditions does trial NCT07019844 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma (HCC).
Who is sponsoring clinical trial NCT07019844?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07019844 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma (HCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07019844's enrollment target sits among peer trials
90 11th of 15 higher than 5 of 15 other Hepatocellular Carcinoma (HCC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma (HCC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RECRUITING · Phase 1
-
The Dragon PLC Trial (DRAGON-PLC)
RECRUITING · NA
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
RECRUITING
-
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI